GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » aTyr Pharma Inc (FRA:471A) » Definitions » 3-Year EPS without NRI Growth Rate

aTyr Pharma (FRA:471A) 3-Year EPS without NRI Growth Rate : 19.00% (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is aTyr Pharma 3-Year EPS without NRI Growth Rate?

aTyr Pharma's EPS without NRI for the three months ended in Dec. 2023 was €-0.23.

During the past 3 years, the average EPS without NRI Growth Rate was 19.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 41.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was 34.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 11 years, the highest 3-Year average EPS without NRI Growth Rate of aTyr Pharma was 59.20% per year. The lowest was -7.10% per year. And the median was 33.25% per year.


Competitive Comparison of aTyr Pharma's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, aTyr Pharma's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


aTyr Pharma's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, aTyr Pharma's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where aTyr Pharma's 3-Year EPS without NRI Growth Rate falls into.



aTyr Pharma 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


aTyr Pharma  (FRA:471A) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


aTyr Pharma 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of aTyr Pharma's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


aTyr Pharma (FRA:471A) Business Description

Industry
Traded in Other Exchanges
Address
10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

aTyr Pharma (FRA:471A) Headlines

No Headlines